Laboratorios Farmaceuticos Rovi dividend and valuation
Valuation
Laboratorios Farmaceuticos Rovi paid €0.96 per share in dividends over the last 12 months (yield 1.5%). Last ex-dividend date: July 13, 2026. The P/E ratio is 16.0. The average price target of 9 analysts is €75.22.
Data as of November 20, 2026
Laboratorios Farmaceuticos Rovi compared with similar companies
Laboratorios Farmaceuticos Rovi's P/E (trailing 12 months): 16.0, −17% against the median of a group of 10 similar companies (19.4).
| Metric | Laboratorios Farmaceuticos Rovi | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 16.0 | 19.4 | 17.1 – 25.7 | Low |
| Forward P/E | 19.9 | 15.5 | 14.4 – 20.0 | Middle |
| EV/EBITDA | 17.5 | 13.3 | 9.36 – 14.7 | High |
| Price/book | 4.29 | 2.83 | 1.94 – 3.28 | High |
| Price/sales | 4.04 | 2.22 | 2.00 – 3.57 | High |
| Gross margin | 66.2% | 65.6% | 47.7% – 77.1% | Middle |
| Operating margin | 20.2% | 20.2% | 13.7% – 23.9% | Middle |
| Net margin | 24.8% | 12.8% | 9.9% – 15.5% | High |
| ROE | 28.7% | 15.4% | 10.7% – 16.8% | High |
| Debt/equity | 0.13 | 0.36 | 0.23 – 0.67 | Low |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Laboratorios Farmaceuticos Rovi: valuation over time
On the latest fiscal year's earnings (2025), Laboratorios Farmaceuticos Rovi's P/E today is 23.0, in line with the median of its last 10 fiscal years (25.1; between 9.66 and 49.9 from 2016 to 2025). Relative to earnings, it costs about the same as in the past. The dividend yield (1.5%) is in line with the median of the last 10 fiscal years (1.4%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | €63.50 | €2.75 | 23.1 | €0.96 | 1.5% |
| 2024 | €62.95 | €2.67 | 23.6 | €0.94 | 1.5% |
| 2023 | €60.20 | €3.20 | 18.8 | €1.10 | 1.8% |
| 2022 | €36.06 | €3.73 | 9.66 | €1.29 | 3.6% |
| 2021 | €73.80 | €2.76 | 26.7 | €0.96 | 1.3% |
| 2020 | €37.90 | €1.10 | 34.4 | €0.38 | 1.0% |
| 2019 | €24.40 | €0.71 | 34.3 | €0.18 | 0.7% |
| 2018 | €17.45 | €0.35 | 49.9 | €0.08 | 0.5% |
| 2017 | €15.65 | €0.35 | 44.8 | €0.12 | 0.8% |
| 2016 | €12.33 | €0.53 | 23.3 | €0.18 | 1.5% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- €3.34B
- Enterprise value
- €3.43B
- PEG
- 1.26
- EV/revenue
- 4.14
Profitability and growth
- ROA
- 10.2%
- ROIC
- 12.3%
- Revenue growth (year over year)
- 26.4%
- Earnings growth (year over year)
- 246.7%
Financial health
- Total cash
- €70.92M
- Total debt
- €100.95M
- Current ratio
- 2.68
- Quick ratio
- 1.50
- Altman Z-Score
- 8.37
- Piotroski F-Score
- 5.00
Dividends
- Annual dividend per share
- €0.96
- Dividend yield
- 1.5%
- Payout ratio
- 23.5%
- Ex-dividend date
- July 13, 2026
Analysts and estimates
- Average price target
- €75.22
- Median price target
- €76.00
- High price target
- €89.00
- Low price target
- €67.00
- Analysts with a price target
- 9
- Consensus
- Buy
- Forward EPS
- €3.29
- EPS estimate, current year
- €3.04
Shares and trading
- Beta
- 0.28
- Average volume
- 102.81K
- Shares outstanding
- 51.14M
- Float
- 16.2M
- Institutional ownership
- 16.9%
- Insider ownership
- 68.2%
